FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029690583> ?p ?o ?g. }

• W2029690583 endingPage "207" @default.
• W2029690583 startingPage "202" @default.
• W2029690583 abstract "Retinoids have been shown to be effective regulators of cell proliferation and differentiation in many human cancers. The major biologic activity of the retinoids is mediated by two families of nuclear receptors: retinoic acid receptors (RARs) and retinoid X receptors (RXRs). ALRT 1550 is one of the most potent RAR selective retinoids discovered to date, with 10-100 times more activity than ATRA in competitive binding and cotransfection assays and 300 times more inhibiting activity against proliferation of cervical carcinoma cell. To evaluate the role of ALRT 1550 in ovarian cancer, the growth inhibitory activity of ALRT 1550 was determined in the ATRA-resistant ovarian cancer cell line SKOV-3 and ovarian cancer cell line 2774 after exposure to concentrations of 0.1, 1, 2.5, 5, and 10 microM for 7 days. SKOV-3 showed 51%, 53%, and 68% cell growth inhibition after treatment with ALRT 1550 at concentrations of 2.5, 5, and 10 microM, respectively, and the 2774 cell line showed 46% inhibition after treatment at 10 microM. Because interferon (IFN)-gamma was found to synergistically amplify the growth inhibition of retinoids in cultured breast cancer cells, we investigated the combination of ALRT 1550 with IFN-gamma in two ovarian cancer cell lines. ALRT 1550 (5 microM) in combination with IFN-gamma at a concentration of 500 U/ml inhibited cell growth of SKOV-3 by as much as 81% (CI = 1.88). This is a 28% greater effect than with ALRT alone. Cell line 2774 showed a 69% cell growth inhibitory effect with ALRT 1550 (5 microM) in combination with IFN-gamma at a concentration of 1000 U/ml (CI = 1.03). ALRT 1550 and IFN-gamma may act synergistically in the SKOV-3 ovarian cancer cell line and additively in the 2774 cell line. In conclusion, ALRT 1550 may be a promising drug with a high biologic modulating activity against ovarian cancer. In combination with IFN-gamma, additive and perhaps synergistic effects may be seen in some ovarian cancer cell lines. Combining these two biologic modifiers for the treatment of ovarian cancer may lower the effective dose of the retinoids, thus decreasing their side effects." @default.
• W2029690583 created "2016-06-24" @default.
• W2029690583 creator A5009043320 @default.
• W2029690583 creator A5059178806 @default.
• W2029690583 creator A5068074506 @default.
• W2029690583 creator A5071228494 @default.
• W2029690583 creator A5078453039 @default.
• W2029690583 creator A5082953093 @default.
• W2029690583 creator A5089486616 @default.
• W2029690583 date "2002-03-01" @default.
• W2029690583 modified "2023-09-28" @default.
• W2029690583 title "Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines" @default.
• W2029690583 cites W1857381743 @default.
• W2029690583 cites W1964322465 @default.
• W2029690583 cites W1978052764 @default.
• W2029690583 cites W1988827270 @default.
• W2029690583 cites W1994110056 @default.
• W2029690583 cites W2003959071 @default.
• W2029690583 cites W2023317094 @default.
• W2029690583 cites W2031474650 @default.
• W2029690583 cites W2037077714 @default.
• W2029690583 cites W2051199526 @default.
• W2029690583 cites W2066055985 @default.
• W2029690583 cites W2076122114 @default.
• W2029690583 cites W2080612628 @default.
• W2029690583 cites W2141354259 @default.
• W2029690583 cites W2154015002 @default.
• W2029690583 cites W2228077492 @default.
• W2029690583 cites W2328421677 @default.
• W2029690583 cites W2409496467 @default.
• W2029690583 doi "https://doi.org/10.1046/j.1525-1438.2002.01084.x" @default.
• W2029690583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11975681" @default.
• W2029690583 hasPublicationYear "2002" @default.
• W2029690583 type Work @default.
• W2029690583 sameAs 2029690583 @default.
• W2029690583 citedByCount "6" @default.
• W2029690583 countsByYear W20296905832013 @default.
• W2029690583 crossrefType "journal-article" @default.
• W2029690583 hasAuthorship W2029690583A5009043320 @default.
• W2029690583 hasAuthorship W2029690583A5059178806 @default.
• W2029690583 hasAuthorship W2029690583A5068074506 @default.
• W2029690583 hasAuthorship W2029690583A5071228494 @default.
• W2029690583 hasAuthorship W2029690583A5078453039 @default.
• W2029690583 hasAuthorship W2029690583A5082953093 @default.
• W2029690583 hasAuthorship W2029690583A5089486616 @default.
• W2029690583 hasConcept C121608353 @default.
• W2029690583 hasConcept C126322002 @default.
• W2029690583 hasConcept C134018914 @default.
• W2029690583 hasConcept C1491633281 @default.
• W2029690583 hasConcept C170493617 @default.
• W2029690583 hasConcept C2775954498 @default.
• W2029690583 hasConcept C2779707156 @default.
• W2029690583 hasConcept C2779963572 @default.
• W2029690583 hasConcept C2780427987 @default.
• W2029690583 hasConcept C2781121885 @default.
• W2029690583 hasConcept C502942594 @default.
• W2029690583 hasConcept C54355233 @default.
• W2029690583 hasConcept C55493867 @default.
• W2029690583 hasConcept C62112901 @default.
• W2029690583 hasConcept C71924100 @default.
• W2029690583 hasConcept C81885089 @default.
• W2029690583 hasConcept C86803240 @default.
• W2029690583 hasConceptScore W2029690583C121608353 @default.
• W2029690583 hasConceptScore W2029690583C126322002 @default.
• W2029690583 hasConceptScore W2029690583C134018914 @default.
• W2029690583 hasConceptScore W2029690583C1491633281 @default.
• W2029690583 hasConceptScore W2029690583C170493617 @default.
• W2029690583 hasConceptScore W2029690583C2775954498 @default.
• W2029690583 hasConceptScore W2029690583C2779707156 @default.
• W2029690583 hasConceptScore W2029690583C2779963572 @default.
• W2029690583 hasConceptScore W2029690583C2780427987 @default.
• W2029690583 hasConceptScore W2029690583C2781121885 @default.
• W2029690583 hasConceptScore W2029690583C502942594 @default.
• W2029690583 hasConceptScore W2029690583C54355233 @default.
• W2029690583 hasConceptScore W2029690583C55493867 @default.
• W2029690583 hasConceptScore W2029690583C62112901 @default.
• W2029690583 hasConceptScore W2029690583C71924100 @default.
• W2029690583 hasConceptScore W2029690583C81885089 @default.
• W2029690583 hasConceptScore W2029690583C86803240 @default.
• W2029690583 hasIssue "2" @default.
• W2029690583 hasLocation W20296905831 @default.
• W2029690583 hasLocation W20296905832 @default.
• W2029690583 hasOpenAccess W2029690583 @default.
• W2029690583 hasPrimaryLocation W20296905831 @default.
• W2029690583 hasRelatedWork W1770611506 @default.
• W2029690583 hasRelatedWork W1977386090 @default.
• W2029690583 hasRelatedWork W2001503472 @default.
• W2029690583 hasRelatedWork W2020120224 @default.
• W2029690583 hasRelatedWork W2085880054 @default.
• W2029690583 hasRelatedWork W2107855445 @default.
• W2029690583 hasRelatedWork W2139860903 @default.
• W2029690583 hasRelatedWork W2168903836 @default.
• W2029690583 hasRelatedWork W2442470032 @default.
• W2029690583 hasRelatedWork W4232351329 @default.
• W2029690583 hasVolume "12" @default.
• W2029690583 isParatext "false" @default.
• W2029690583 isRetracted "false" @default.
• W2029690583 magId "2029690583" @default.

• next